
















Purpose:	 Endocrine	 therapy	 is	 the	 standard	 treatment	 for	 estrogen	 receptor-posi\ve	 (ER+)	 breast	
cancer.	 Despite	 its	 efficacy,	 around	 half	 of	 pa\ents	 will	 develop	 resistance	 to	 this	 treatment	 and	
eventually	 relapse.	 Iden\fica\on	of	 effec\ve	and	 reliable	biomarkers	 to	predict	 the	efficacy	of	 en-
docrine	therapy	is	of	crucial	importance	in	the	management	of	ER+	breast	cancer.	Emerging	evidence	
has	revealed	that	the	cell	division	regulator	CDC20	exhibits	an	oncogenic	func\on	and	plays	impor-
































progression	 of	 breast	 cancer	 where	 it	 is	 significantly	 higher	 in	 breast	 cancer	 cells	 and	 high-grade	
primary	tumour	\ssues	[17]	and	indicates	an	aggressive	course	of	disease	risk	[18].	We	aimed	to	in-





The	Molecular	 Taxonomy	 of	 Breast	 Cancer	 Interna\onal	 Consor\um	 (METABRIC)	 [19],	 comprising	
1,506	ER+	breast	cancer,	was	used	as	a	discovery	cohort	to	analyse	and	explore	the	prognos\c	value	
of	 CDC20	mRNA	and	 its	 role	 as	 predic\ve	biomarker	 of	 clinical	 outcome	 for	 pa\ents	who	 treated	
with	endocrine	therapy,	Table	1.	













apy	was	 given.	 Premenopausal	 pa\ents	within	 the	moderate	 and	 poor	 prognos\c	NPI	were	 given	











\ssue	 microarrays	 (TMAs)	 sec\ons	 using	 Novolink	 polymer	 detec\on	 system	 (Leica	 Biosystems,	
RE7150-K),	 detailed	method	was	 described	 in	 previous	 publica\on	 [22].	 Sec\ons	were	 incubated,	
overnight	at	4	°C,	with	the	primary	CDC20	an\body	diluted	at	1:500.	CDC20	immunoreac\vity	was	










fined	 as	 the	 \me	 in	months	 from	diagnosis	 un\l	 developing	 local	 or	 regional	 recurrence.	 Distant-
metastasis	free	survival	(DMFS)	was	defined	as	the	\me	in	months	from	diagnosis	un\l	developing	












Benjamini–Hochberg	procedure	 for	mul\ple	 test	 correc\on	was	performed.	 P	 value	of	 ≤	 0.05	was	
considered	 significant.	 The	 dichotomisa\on	 of	 CDC20	mRNA	 and	 protein	 expression	 into	 low	 and	





expression	was	observed	 in	 636	 cases	 (42%).	 CDC20	protein	 expression	was	 localised	 to	 the	 cyto-




CDC20	mRNA	 expression	was	 associated	with	 aggressive	 clinico-pathological	 parameters	 including	


























pared	 with	 CDC20	 low	 expression.	 These	 observa\ons	 were	 validated	 in	 the	 KM-Plocer	 dataset	
where	pa\ents	who	received	endocrine	therapy	with	high	CDC20	mRNA	showed	poor	benefit	form	






























CDC20	has	a	key	 roles	 in	ac\va\ng	 the	APC/C	 to	 ini\ate	anaphase	and	 late	mitosis	exit	 in	 the	cell	
cycle	 [26,8].	 CDC20	has	 also	been	 shown	 to	be	 a	promising	prognos\c	marker	 for	 a	 variety	of	 tu-






protein	was	not	prognos\c,	 it	 is	 likely	that	CDC20	expression	plays	a	vital	role	 in	ER+	breast	cancer	
progression.	
Prolifera\on	 has	 a	 key	 role	 in	 the	 clinical	 behaviour	 of	 breast	 cancer	 and	 correlates	 strongly	with	
poor	clinical	outcome	and	drug	resistance.	In	addi\on	to	ER	and	PR,	markers	of	prolifera\on	seems	
to	influence	biological	and	clinical	behaviour	of	ER+	breast	cancer	[19].	 In	 light	of	this,	our	findings	
showed	 that	 high	 CDC20	mRNA	 expression	was	 posi\vely	 correlated	with	 prolifera\on-associated	
genes,	 including	MKI67,	 CCNB1,	 CCNA2	 and	CCND1.	 This	 supports	 the	 results	 of	 previous	 studies,	
which	reported	that	knockdown	of	CDC20	decreased	cell	prolifera\on	and	induced	G2/M	cell	cycle	




used	 currently	 both	 for	 clinical	 diagnosis	 to	 classify	 breast	 cancer	 pa\ents	 and	 as	 a	 guide	 to	 en-

























The	 level	of	 agreement	 in	our	 study	between	 results	of	CDC20	mRNA	and	protein	expression	was	
poor.	This	discrepancy	could	be	explained	by	several	possibili\es,	 including	biological	and	technical	






that	CDC20	mRNA	expression	 in	ER+	breast	 cancer	 is	a	poten\ally	predic\ve	 for	 selec\ng	pa\ents	





























endocrine	 therapy	 in	 pa\ents	with	 ER+ breast	 cancer	 aeer	 endocrine	 treatment	 using	 KM-Plocer	



















































































































































































































































































































































































P< 0.0001P< 0.0001P< 0.0001P< 0.0001
